New hope for intimacy after breast cancer treatment?
NCT ID NCT03707340
Summary
This study is testing whether it is safe and practical for breast cancer survivors to take a medication called flibanserin while they are on their standard hormone therapy (tamoxifen or similar drugs). The researchers want to see if flibanserin can help improve low sexual desire, a common side effect of these cancer treatments. They are enrolling about 43 women who have finished their primary cancer treatment but are struggling with this specific issue.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan - Kettering Cancer Center
New York, New York, 10021, United States
-
Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Cancer Center @ Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Norwalk Hospital
Norwalk, Connecticut, 06850, United States
Conditions
Explore the condition pages connected to this study.